[Bonus-malus regulations in the framework of the AVWG guideline-suitable migraine therapy are possible].
D002986:Clinical Trials as Topic; D018592:Cross-Over Studies; D004335:Drug and Narcotic Control; D005858:Germany; D006801:Humans; D008881:Migraine Disorders / Q000188:drug therapy*; D015337:Multicenter Studies as Topic; D017060:Patient Satisfaction; D017410:Practice Guidelines as Topic; D011446:Prospective Studies; D017366:Serotonin Receptor Agonists / Q000008:administration & dosage / Q000627:therapeutic use*; D018170:Sumatriptan / Q000008:administration & dosage / Q000627:therapeutic use*; D013997:Time Factors; D014230:Triazoles / Q000008:administration & dosage / Q000627:therapeutic use*; D014363:Tryptamines / Q000008:administration & dosage / Q000627:therapeutic use*; D014662:Vasoconstrictor Agents / Q000008:administration & dosage / Q000627:therapeutic use*
D017366:Serotonin Receptor Agonists; D014230:Triazoles; D014363:Tryptamines; D014662:Vasoconstrictor Agents; C093622:rizatriptan; D018170:Sumatriptan